Document is current
Any future updates will be listed below
-
Authors
Heras-Murillo, Ignacio
Mañanes, Diego https://orcid.org/0000-0001-7247-6794
Munné, Pablo https://orcid.org/0009-0004-6801-1213
Núñez, Vanessa
Herrera, Jessica
Catalá-Montoro, Mauro
Alvarez, Maite https://orcid.org/0000-0002-5969-9181
del Pozo, Miguel A. https://orcid.org/0000-0001-9077-391X
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
Wculek, Stefanie K. https://orcid.org/0000-0001-5565-8561
Sancho, David https://orcid.org/0000-0003-2890-3984
- License Information
-
More Information
Article History
Received: 21 November 2023
Accepted: 17 March 2025
First Online: 9 April 2025
Competing interests
: S.K.W. serves as a consultant for ONA therapeutics (Barcelona, Spain). D.S. has a research collaboration agreement with Inmunotek SL (Alcala de Henares). I.M. reports grant funding from Roche, BMS, Astrazeneca, Genmab, and Pharmamar and advisory roles with Roche-Genentech, Bristol-Myers Squibb, Astrazeneca, F-Star, Genmab, Third Rock Ventures, Amunix Pharmaceuticals, Alligator, Bioncotech, Boston Therapeutics, Bright Peak, Numab, Catalym, Pieris, and Pharmamar. The rest of the authors declare no competing interests.
